Around the world -- and even right here in the United States -- there are diseases that cause tremendous human suffering and wreak havoc on the lives of millions. Together with our network of global partners, the Sabin Vaccine Institute works tirelessly to reduce the impact of vaccine preventable and neglected tropical diseases. Find out more about our three main programs:

Global Network

The Global Network for Neglected Tropical Diseases works to raise awareness political will and funding necessary to control and eliminate the seven most common neglected tropical diseases (NTDs).

“Drug donations and research and development support from pharmaceutical companies are just the beginning of a comprehensive collaboration between the private sector, NGOs and country governments to meet our 2020 elimination targets."  

-Dr. Neeraj Mistry, Managing Director, Global Network for Neglected Tropical Diseases


Vaccine Advocacy & Education

The Vaccine Advocacy and Education program at Sabin is dedicated to reducing the burden of preventable diseases by bringing together key stakeholders and leaders in government, private sector and civil society in order to foster cooperation, share information and best practices and develop improved vaccine policy and access.

“I have no doubt that the 21st century will be known as the century of vaccines. A century of vaccines could be extraordinary as long as we ensure that available vaccines reach everyone in the world who needs them.”

-Dr. Ciro de Quadros, Executive Vice-President, Sabin Vaccine Institute


Vaccine Development

Since 2000, our President, Dr. Peter Hotez, has led the Sabin Vaccine Institute Product Development Partnership’s (Sabin PDP) progress in developing vaccines for diseases of the world’s poorest people. More than a decade of work has resulted in a low-cost model that serves as a blueprint for developing vaccines that otherwise have no commercial market.

“We are filling a gap to produce a vaccine for underrepresented populations, where no traditional commercial market currently exists.”

 -Dr. Peter Hotez, President, Sabin Vaccine Institute